Atlas Trials

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

Clinical trial NCT07573631 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT07573631
Sponsor
BioMarin Pharmaceutical
Status
ENROLLING_BY_INVITATION
Phase
Phase 2
Study type
INTERVENTIONAL
Duchenne Muscular Dystrophy (DMD)
Start date
2026-04-20
Primary completion
2031-12-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.